Differentiating Psoriasis from Eczema
Psoriasis presents with well-demarcated, thick, silvery-scaled plaques typically on extensor surfaces (elbows, knees) and scalp, while eczema shows poorly-demarcated, erythematous patches with fine scaling on flexural areas (antecubital/popliteal fossae) that are intensely pruritic.
Clinical Differentiation Algorithm
Location Pattern
- Psoriasis: Extensor surfaces (elbows, knees), scalp, lower back, nails (pitting, oil spots)
- Eczema: Flexural areas (inner elbows, behind knees), face, neck, hands
- Overlap zones: Palms, soles, scalp can present with both 1, 2
Morphology
Psoriasis:
- Well-demarcated borders
- Thick, silvery-white scales
- Auspitz sign (pinpoint bleeding when scale removed)
- Salmon-pink plaques
Eczema:
- Poorly-demarcated borders
- Fine, dry scaling
- Lichenification (thickened skin from chronic scratching)
- Weeping/crusting in acute phases
Symptom Profile
- Psoriasis: Minimal to moderate pruritus, mental stress and inadequate sleep are primary triggers 3
- Eczema: Intense pruritus (often worse at night), humid environment and dust are primary triggers 3
Histopathology When Needed
- Psoriasis: Acanthosis, hypogranulosis, Munro microabscesses, elongated rete ridges
- Eczema: Spongiosis, preserved granular layer
- Note: Dermatopathology shows only fair inter-observer agreement (κ = 0.31) with 76.9% accuracy 4. Overlapping cases may show mixed histology 1.
Advanced Diagnostic Tools
When clinical and histologic features are ambiguous, molecular testing (NOS2/CCL27 RT-qPCR) achieves 87-92% sensitivity and 82-84% specificity, significantly outperforming dermatopathology in diagnostically challenging cases 4.
Initial Treatment Approach
For Psoriasis (Localized Disease)
Use moderate to high-potency topical corticosteroids (class 2-5) for trunk/extremities and class 1 (ultrahigh-potency) for thick, chronic plaques, applied for up to 4 weeks 5.
- Body/extremities: Class 2-5 corticosteroids (e.g., triamcinolone 0.1%, betamethasone dipropionate 0.05%)
- Thick plaques: Class 1 corticosteroids (e.g., clobetasol propionate 0.05%, halobetasol propionate 0.05%)
- Face/intertriginous areas: Lower potency (class 6-7) to avoid atrophy
- Scalp: Any class 1-7 corticosteroid for minimum 4 weeks 5
- Efficacy: Class 1 corticosteroids achieve 68-92% improvement in 2 weeks 5
For Eczema (Atopic Dermatitis)
Use topical corticosteroids matched to severity and location, with low-potency agents for face/flexures and moderate-potency for body, combined with aggressive moisturization 2, 6.
- Acute weeping lesions: Wet compresses followed by mid-potency corticosteroids
- Chronic lichenified areas: Higher potency corticosteroids (class 2-3)
- Face/neck: Low-potency corticosteroids (class 6-7) or calcineurin inhibitors
- Maintenance: Daily emollients, trigger avoidance (dust, humidity control)
Critical Pitfalls to Avoid
Misdiagnosis Risk
- Scalp involvement: Both conditions commonly affect scalp; look for body distribution patterns 2
- Hand/foot lesions: Highest overlap zone—consider biopsy or molecular testing if treatment fails 1
- Coexisting disease: 20% of patients may have both conditions simultaneously 1
Treatment Complications
- Prolonged high-potency corticosteroids: Risk of skin atrophy, especially on face, flexures, and forearms 5
- Biologic-induced switching: Anti-IL-17 therapy for psoriasis can induce eczema (31 cases reported); dupilumab for eczema can induce psoriasis (19 cases reported) 1
- Duration limits: Topical corticosteroids beyond 4 weeks require careful physician supervision 5
When Initial Treatment Fails
If topical therapy fails after 4 weeks or diagnostic uncertainty persists, consider:
- JAK inhibitors (effective for both conditions and overlap syndromes) 1
- IL-23 inhibitors for psoriasis-predominant cases 1
- Molecular testing for definitive differentiation 4
The immunologic spectrum concept suggests these may represent poles of shared pathways (Th17/Th1 in psoriasis vs. Th2 in eczema), with some patients showing mixed profiles requiring tailored systemic therapy 1, 7.